Molecular Hydrogen Therapy — A Review on Clinical Studies and Outcomes

Executive summary

This is the best available answer to 'what has molecular hydrogen actually been shown to do in people?'

The authors note that a simple search for hydrogen gas across medical databases returns more than 2,000 publications relating to it as a potential new drug substance, and that a parallel search of clinical trial registers also generates many hits. From that, they assess 81 identified clinical trials and 64 scientific publications on human studies.

Positive indications have been found across major disease areas including cardiovascular diseases, cancer, respiratory diseases, central nervous system disorders and infections, among others. The review also examines available administration methods and the challenges they pose - specifically hydrogen's explosive hazard and its low solubility in water - along with possible future technologies to mitigate them.

The framing is what a buyer should notice. The review closes by asking whether hydrogen gas will be a new drug substance in future clinical practice, and if so, what the administration form and clinical indications might be. Those are open questions, posed by specialists reviewing the whole human literature.

A field with 81 registered trials and an unresolved question about whether it will become a therapy is an active research area. It is not an established one, and equipment sold on the strength of it should be described accordingly.

Why this research matters

Molecular hydrogen is marketed with unusual confidence relative to its evidence base. This review is the correct reference point because it counts the human studies rather than citing selected favourable ones.

It also draws the administration-route distinction that most marketing collapses. Inhaled hydrogen gas and hydrogen-rich water are different exposures with different solubility limits, different doses and largely different study populations.

What the researchers found

The review identifies 81 clinical trials and 64 scientific publications reporting human studies of hydrogen therapy.

Positive indications have been found in major disease areas including cardiovascular diseases, cancer, respiratory diseases, central nervous system disorders, infections and others.

The available administration methods are reviewed, along with the challenges they pose - hydrogen's explosive hazard and its low solubility - and possible future innovative technologies to mitigate them.

The review concludes by posing rather than answering the central question: will hydrogen gas be a new drug substance in future clinical practice, and if so, in what administration form and for what clinical indications.

No pooled effect estimates, confidence intervals or p-values are generated by this review, and none are reproduced here.

What the results mean

There is genuine, substantial and ongoing human research in this field. That distinguishes molecular hydrogen from technologies with no clinical literature at all, and it deserves acknowledgement.

'Positive indications' across many disease areas is a phrase that requires care. It describes signals worth pursuing, not demonstrated treatments. A field producing positive early signals across cardiovascular, cancer, respiratory, neurological and infectious disease simultaneously is either detecting a genuinely fundamental mechanism or is at the stage where small, short, heterogeneous studies produce favourable results in many directions. Both happen.

The honest reading is that this is an active research area at an early clinical stage, and that its own reviewers regard the therapeutic question as open.

Strengths and limitations

Strengths

• Counts and characterises the human clinical literature rather than relying on preclinical extrapolation.
• Covers both clinical trial registrations and published human studies.
• Addresses administration routes and their technical constraints explicitly, including the flammability hazard.
• Discusses solubility, which is the practical limit on hydrogen-rich water dosing.
• Frames the therapeutic question as open rather than settled.
• Published in a peer-reviewed journal by a pharmacy research group.

Limitations

• Narrative review with no formal bias assessment or quality grading.
• No meta-analysis or pooled estimates.
• Individual trial sample sizes, durations and effect sizes not reported in the source abstract.
• Breadth of disease areas covered makes it difficult to assess any single indication in depth.
• Positive-indication reporting does not account for publication bias.
• Does not separately assess general wellness use, which is what consumer equipment is sold for.

Evidence in context

The clinical picture has not consolidated. A separate 2021 review traces hydrogen gas therapy from preclinical work to clinical trials, noting its use in acute medical settings including ischaemia-reperfusion injury and organ preservation - contexts far removed from home wellness use.

On the water side, a 2021 randomised controlled pilot trial of hydrogen-rich water in adults aged 70 and over found significant differences on a small number of biomarkers and no significant differences on most other outcomes. That is a fair illustration of what the current best water evidence looks like: pilot scale, mixed results.

No large, well-powered randomised trial of hydrogen-rich water for a general wellness outcome has been published as far as we are aware.

Related research

1. The effects of 6-month hydrogen-rich water intake on molecular and phenotypic biomarkers of aging in older adults aged 70 years and over: a randomized controlled pilot trial Zanini D, Todorovic N, Korovljev D, et al. Experimental Gerontology 155:111574. 2021. PMID 34601077; doi:10.1016/j.exger.2021.111574.A six-month randomised pilot trial of hydrogen-rich water in older adults - the most relevant single study for a water generator purchase.
2. Hydrogen gas therapy: from preclinical studies to clinical trials Sano M, Tamura T. Current Pharmaceutical Design 27(5):650-658. 2021. PMID 33349213; doi:10.2174/1381612826666201221150857.Traces hydrogen gas therapy from preclinical work to clinical trials, largely in acute medical settings.
3. General wellness: policy for low risk devices - guidance for industry and FDA staff U.S. FDA, Center for Devices and Radiological Health. Docket FDA-2014-N-1039. 2019. CDRH guidance.FDA guidance on where general wellness claims end and disease claims begin - directly relevant to how this equipment may be marketed.
4. Health products compliance guidance U.S. Federal Trade Commission, Bureau of Consumer Protection. 2022. Replaces the 1998 Dietary Supplements advertising guide.FTC standard for substantiating health claims in advertising.